 |
|
|
| |
Ultra-Long-Acting MPT Injectable with Dolutegravir and Levonorgestrel for HIV PrEP and Contraception
|
| |
| |
CROI 2026 Feb 22-25 Denver
Thy Le1, Ivana Massud2, Mackenzie L. Cottrell 3 Jasmine King1, Craig Sykes3, Amanda Schauer3, Angela D.M. Kashuba3, Walid Heneine2 ,J. Gerardo Garcia-Lerma2, Charles W. Dobard2, S. Rahima Benhabbour*1,4
1Lampe Joint Department of Biomedical Engineering at NCSU/UNC-CH, Chapel Hill, USA, 2Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, & TB Prevention, Centers for Disease Control & Prevention, Atlanta, USA 3Division of Pharmacotherapy & Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, USA, 4Division of Pharmacoengineering & Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, Chapel Hill, USA
Background: HIV and unintended pregnancy remain intersecting global burdens on women’s health. Adherence challenges limit the effectiveness of oral HIV PrEP and contraception. We propose to develop an ultra-long-acting
(ULA) in-situ forming implant (ISFI) multipurpose prevention technology (MPT) co-formulating dolutegravir (DTG) and levonorgestrel (LNG) as a once-yearly injectable to reduce dosing burden and enhance compliance.
|
| |
|
|
|
|
|
